Gene therapy as well as methods capable of returning cells to a pluripotent state (iPS) have enabled the correction of genetic deficiencies in syngenic adult progenitors, reducing the need for immunosuppression in cell therapy approaches. However, in diseases involving mutations that lead to the complete lack of a protein, such as Duchenne muscular dystrophy, the main immunogens leading to rejection of transplanted cells are the therapeutic proteins themselves. In these cases even iPS cells would not circumvent the need for immunosuppression, and alternative strategies must be developed. One such potential strategy seeks to induce immune tolerance using hematopoietic stem cells originated from the same donor or iPS line from which the therapeutic progenitors are derived. However, donor hematopoietic stem cells (HSCs) are available in limiting numbers and embryonic stem (ES) cell-derived HSCs engraft poorly in adults. While these limitations have been circumvented by ectopic expression of HOXB4, overexpression of this protein is associated with inefficient lymphoid reconstitution. Here we show that adult HSCs expanded with a NUP98-HOXA10hd fusion protein sustain long-term engraftment in immunologically mismatched recipients and generate normal numbers of lymphoid cells. In addition, NUP98-HOXA10hd-expanded cells induce functional immune tolerance to a subsequent transplant of myogenic progenitors immunologically matched with the transplanted HSCs.
INTRODUCTION
trigger an immune reaction due to the immunogenicity of the wild-type protein itself. Therefore, independent of the source of donor cells, for DMD and a number of Duchenne muscular dystrophy (DMD) and related forms of muscular diseases are characterized by severe similar genetic conditions in which the therapeutic gene product is seen as non-self by the patient's immune sys-muscle damage, often leading to premature death. Current treatments that aim to extend a patient's mobility tem, long-term blockade of the immune response is required. To this end, the induction of immune tolerance and survival are insufficient. Among the potential new therapies for DMD, one of the most promising clinical represents a viable strategy. Currently, the main approach used to dampen im-approaches relies on intramuscular transplantation of muscle stem cells from a healthy donor (10, 14, 16, 22) . mune rejection uses immunosuppressive drugs, which have significant side effects, including tumor growth, in-Satellite cell allotransplantation, like any other allograft, raises the problem of immune recognition and rejection fections, metabolic disorders, or organ damage. An alternative to this pharmacological intervention is induc-of the therapeutic donor cells, necessitating immunosuppression in order to facilitate efficient muscle engraft-tion of donor-specific tolerance by bone marrow (BM) transplantation (24) . Stable hematopoietic chimerism ment (5, 8) . Induced pluripotent stem (iPS) cells could offer novel alternatives to circumvent allogenic trans-can lead to thymic and peripheral deletion of lymphocytes reactive towards either donor or host, which results plant involving immunosuppression treatment. However, in the case of DMD, where dystrophin is absent, in long-term tolerance and limited graft-versus-host disease (GVHD). Such a protocol has been in existence for the transplantation of wild-type cells has been shown to 1100 EVEN ET AL. more than 50 years (4) and has been utilized success-for BM repopulation without inducing an imbalance between myeloid and lymphoid cell production (13, 19) . fully in several solid organ transplants (7) . Despite the recognition that hematopoietic stem cell (HSC) trans-Here we explore the ability of NUPA10hd-expanded HSCs to induce functional immune tolerance. Our data plants can lead to robust tolerance, myeloablative conditioning for HSC engraftment, generally used for diseases show that expanded NUPA10hd-infected HSCs can efficiently reconstitute fully immunologically mismatched such as leukemia, is considered too toxic for routine use in organ transplantation situations. The only protocols recipient mice and that the resulting chimeric mice display long-term tolerance to the transplantation of myo-currently accepted in such cases are noncytoreductive and usually require larger numbers of HSCs than are genic progenitor cells immunologically matched with the transplanted HSCs. routinely available in order to obtain chimerism (24) . Two alternative approaches may circumvent the prob-MATERIALS AND METHODS lems caused by the limiting numbers of HSCs. The first Retroviral Vectors entails in vitro expansion of HSCs, although, after years of focused research, our ability to expand unmodified
The generation of MSCV-NUP98-HOXA10hd-IRES-HSCs in vitro is still severely limited. The second ap-GFP (NUPA10hd) viral vector has been described preproach is based on the use of embryonic stem (ES) cells, viously (15). which can be expanded to large numbers and induced to Animals form tissue-committed adult-type progenitors, including HSCs. The limitation to this method lies in the inability CD45.1, CD45.2, and GFP + CD45.2 C57BL/6 mice of ES-derived HSCs to efficiently reconstitute BM of (H-2 b ) were bred in-house and maintained in a pathogenadult recipients (12). We have addressed the challenges free environment. GFP + CD45.2 C57BL/6 mice express imposed by either approach by engineering HSCs that GFP ubiquitously from the cytomegalovirus enhanceroverexpress transcription factors of the HOX family or chicken β-actin hybrid promoter (28). Balb/c mice were their derivatives.
purchased from Jackson Laboratories. C57BL/6 CD45.2 The HOX family of homeobox genes has been shown mice, 4-6 weeks of age, were used as donors for bone to play an important role in hematopoiesis (2). Several marrow transplantation. GFP + CD45.2 C57BL/6 mice, studies have reported that overexpression of HOXB4 in-8-10 weeks of age, were used as donors for satellite cell duces the rapid expansion of HSCs ex vivo. Furthertransplantation. C57BL/6 CD45.1 mice, 12 weeks of more, HOXB4 confers the ability upon donor cells to age, were used as syngenic hosts for control groups and fully replenish the numbers of HSCs normally present age-matched Balb/c mice were used as allogenic hosts. in BM without expanding beyond the normal limits, sug-All experiments were approved by the University of gesting that HOXB4-expressing cells are still subject to British Columbia Animal care committee. physiological mechanisms controlling their proliferation Antibodies and Staining Reagent for FACS Sorts (1, 17, 26) . Finally, recent studies have shown that the expression of HOXB4 in ES-derived hematopoietic cells Anti-Gr-1, anti-α7 integrin, and anti-CD3 monoenables their engraftment in adult recipients (11). The clonal antibodies were purified using hybridoma mainprimary drawback of using HOXB4 to overcome limitatained in our laboratory and respectively conjugated to tions in HSC availability or engraftment properties PE (Prozyme) and to Alexa 647 (Invitrogen) according stems from the fact that high levels of this transcription to the manufacturer's instructions. Antibodies against Hfactor skew hematopoietic progenitor differentiation to-2K b conjugated to biotin, anti-C-kit conjugated to PE, wards myeloid lineages, resulting in poor reconstitution and anti-CD45 conjugated to PerCP were purchased of the lymphoid compartment in transplanted recipients from BD Biosciences Pharmingen; anti-Mac-1 conju- (18) . Therefore, we sought to examine the ability of gated to PE, anti-CD3, B220, Mac-1, TER119, Gr-1 other members of the HOX protein family to reconstitute conjugated to PE-Cy7, anti-CD45.2, Sca-1 conjugated to the hematopoietic compartment with normal myeloid/lymeither APC or PE-Cy7 were purchased from eBiosciphoid lineage ratios. Recent work on NUPA10hd, a fuence. Streptavidin conjugated to APC was purchased sion of the N-terminal domain of nucleoporin 98 from Caltag. Hoechst was purchased from Sigma. (NUP98) and the homeodomain only of another member
Purification of Lin − Sca + C-kit + (LSK) Cells of the HOX transcription factor family (HOXA10), has shown promising results in BM reconstitution. Seku-Lin + cells were depleted by staining bone marrow (BM) with antibodies to CD3, B220, Mac-1, TER119, lovic et al. were able to induce more than 1000-fold expansion of HSCs in the short-term in vitro culture and,
Gr-1 (all conjugated to PE-Cy7) and anti-PE magnetic beads followed by separation on an autoMACS (Mil-in contrast to HOXB4, the HOXA10hd fusion protein NUPA10hd-infected HSCs demonstrate a high capacity tenyi Biotec.). The Lin − -enriched fraction was stained with anti-C-kit-PE and Sca-1-APC. Sorting was per-(QImaging) and analyzed using Openlab software (Improvision). formed on a FACSVantage (Becton Dickinson).
Mixed Lymphocyte Reactions (MLR) Infection of LSK Cells With NUPA10hd Retrovirus
Spleens were aseptically removed from terminally Cultures were initiated with sorted LSK mouse bone anesthetized mice before perfusion or fixatives were apmarrow cells. After isolation, cells were prestimulated plied. Tissue was stored in complete media on ice until in the presence of serum and hematopoietic growth facprocessing (DMEM supplemented with 10% fetal botors for a day, exposed to NUP98-HOXA10hd-IRESvine serum, 1% penicillin/streptomycin, 1% L-gluta-GFP (NUPA10hd) retrovirus for 48 h, and then mainmine, 1% nonessential amino acid solution, 1% sodium tained in vitro for 6 more days as previously described pyruvate, and 0.1% β-mercaptoethanol). Individual spleens (13, 19) .
were dissociated by pushing through a 70-µM nylon fil-
Transplant of Infected Cells and Flow
ter (BD Pharmingen) with a syringe plunger. The filter Cytometry Analysis was washed and the recovered cells pelleted in a centrifuge at 1500 rpm for 5 min at 4°C. The pellet was resus-Infected LSK cells were collected 8 days after infecpended in Tris-NH 4 Cl-based cell lysis buffer, incubated tion and sorted for GFP + on a FACSVantage (Becton for 10 min at room temperature, when the reaction was Dickinson). Recipient mice were subjected to a sublethal stopped with 10% serum and the cells washed and coun-8.5 Gy cobalt-60 gamma irradiation dose and received ted. Stimulator cells (antigen presenting cells, or APC) 30-300,000 cells intravenously. The group injected with of C57BL/6 origin were irradiated with 1500 rads in a 30 cells also received 300,000 Sca − cells generated by Gammacell irradiator. Cells were then plated in each magnetic depletion of BM from C57BL/6-CD45.1 mice.
well of flat bottom 96-well tissue culture plates (Nunc).
For chimerism analyses, peripheral blood was collected
To assess tolerance under coculture conditions, 2 × 10 5 from the saphenous vein into heparinized tubes and red responder cells were cultured in the presence of 10 4 , 5 blood cells were lysed with an ammonium chloride solu-× 10 4 , and 10 5 stimulator cells. Controls included wells tion. The remaining white blood cells were stained with containing no stimulator cells, stimulator cells alone, anti-H-2K b -biotin, followed by streptavidin-APC, and and anti-CD3 (2C11, in house) mitogen stimulation. The Gr-1-PE, CD3-PE-Cy7 or Mac-1-PE, B220-PE-Cy7. For cultures were incubated at 37°C, 5% CO 2 for 72 h, when control groups (C57BL/6-CD45.1 hosts) anti-H-2K bthey were pulsed with 1 µCi of [ 3 H]TdR and returned to biotin was replaced by CD45.2-APC.
the incubator for a final 24 h. Cultures were harvested Satellite Cell Sort and Transplantation on to glass filters and subsequently read on a 96-well format Top Count machine. All samples were plated in Muscle cells from GFP + C57BL/6 mice were isolated triplicate and the graphs reflect average cpm ([ 3 H]TdR and myoblasts were sorted as described previously (9). incorporation) ± SE. Briefly, isolated muscle cells were stained with anti-Sca-1-PE Cy7, anti-α7 integrin-Alexa 647, anti-CD31-and RESULTS anti-CD45-PerCP, and sorted on a FACSVantage (Bec-Transplantation of BM Stem/Progenitor Cells ton Dickinson); 30,000 α7 integrin-positive, CD31-, Expressing NUPA10hd Induces Stable Hematopoietic CD45-, and Sca-1-negative cells were injected directly Chimerism in Allogeneic Recipients into the tibialis anterior in 20 µl PBS. Transplanted muscles were harvested and analyzed by immunohistochem-NUPA10hd-expressing HSCs can undergo multilog expansion in short-term liquid culture and subsequently istry 4 weeks after transplant. efficiently reconstitute isogenic recipients. However, the Tissue Analysis performance of NUPA10hd-expanded cells in allogeneic transplants has not been explored. Therefore, we set out Mice were terminally anesthetized and spleens were harvested for mixed lymphocyte reaction (MLR) assays.
to determine whether C57BL/6 (H-2 b ) NUPA10hd-expressing HSCs would effectively generate stable hematopoi-Then, mice were perfused with 50 ml of PBS and with 20 ml of 4% paraformaldehyde in PBS. Limb muscles etic chimerism in fully MHC-mismatched Balb/c (H-2 d ) recipients. The diagram in Figure 1A shows the experi-were collected and postfixed for 2 h in 2% paraformaldehyde and stored overnight in 20% sucrose at 4°C for mental design. FACS-purified LSK stem/progenitor cells were infected with a retrovirus expressing NUPA10hd as cryoprotection. The tissues were embedded in Tissue-Tek OCT, frozen on dry ice, and stored at −80°C until well as GFP. Cultures were initiated with 1.6 × 10 5 purified LSK cells (ϳ55% GFP + ) ( Fig. 1B) or ϳ3,000 trans-processing. Samples were stained with Hoechst and visualized using a Zeiss Axioplan 2 microscope. Images duced HSCs (based on HSC frequency of 1/30 for LSK). After 8 days, the total cell number had increased by over were digitally captured using a charge-coupled device 300-fold with commensurate expansion of transduced cells retained GFP expression ( Fig. 2A ). Across the range of NUPA10hd-LSK transplanted cells, the number HSC content (13). Viable GFP + cells were purified by flow cytometry and transplanted into sublethally irradi-of mice chimeric was found to be proportional to the number of cells injected (Fig. 2B ). Strikingly even with ated Balb/c mice (8.5 Gy). To assess the minimum number of NUPA10hd-expanded cells required to efficiently a transplant dose as low as 1/100,000 of the culture, representing fewer than 0.03 starting HSCs or 9 HSCs achieve chimerism in allogeneic Balb/c recipients, five doses of sorted cells ranging from 1/1,000,000th of the after expansion, significant levels of chimerism were achieved in 1/5 mice. High levels of chimerism were culture to 1/100th of the culture were transplanted. Based on an estimated HSC expansion of 300-fold, this achieved in the majority of mice with as little as 1/ 1,000th of the culture or 3 starting HSCs or 900 HSCs represents a transplant dose range of 0.9 HSCs to 9,000 HSCs, respectively (corresponding to starting equivalent after expansion and in all mice with a maximum transplant does of 1/100th of a culture or the expanded prog-of 0.003 HSCs to 30 HSCs). A parallel control group of Balb/c recipients received 3,000 freshly sorted, unin-eny of only 30 starting HSCs. By comparison, chimerism in recipients of freshly sorted allogeneic LSK cells fected C57BL/6 LSK cells (corresponding to an estimated 100 HSCs). was only achieved in 3/5 mice at transplant dose of 3,000 (ϳ100 HSCs). Furthermore, all chimeric mice Twelve weeks after transplant we measured the frequency of H-2 b (donor C57BL/6)-positive cells within presented high levels of chimerism for all four hematopoietic lineages tested, reflecting a very efficient and the T-cell, B-cell, granulocyte, and monocyte populations to assess peripheral blood chimerism. As expected stable BM marrow reconstitution from donor mice (Fig.  2C) . Importantly, no recipients that received NUPA10hd-due to the inability of untransduced HSCs to survive in extended culture and the anticipated 300-fold expansion transduced cells showed any evidence of myeloproliferative disorder or leukemia up to 3 months posttransplanta-of transduced HSCs, essentially all H-2 b -positive donor tion, consistent with earlier observations (13). Furthermore, Mice With High Level of Chimerism Are Tolerant for Muscle Engraftment the same recipients showed no obvious signs of GVHD, such as facial swelling or diarrhea. These results demonstrate that HSCs can be expanded several hundred fold
To determine whether recipients engrafted with NUPA10hd-expanded HSCs would tolerate subsequent and still sustain long-term donor-specific chimerism in mice bearing a fully mismatched MHC.
transplants of therapeutic cells from the same source, we injected FACS-sorted myogenic progenitors (MPs) into cells (2 × 10 5 ) from NUPA10hd-HSC transplanted mice were harvested 16 weeks after transplantation and cul-the tibialis anterior (TA) muscles of mice that had received HSCs 12 weeks before. Upon transplantation, tured in the presence of 10 4 , 5 × 10 4 , or 10 5 irradiated naive C57BL/6 spleen cells (stimulator cells, or APCs). myogenic progenitors normally fuse with resident myofibers (9). Incorporation of immunologically mis-Cell viability was confirmed by response to anti-CD3 (2C11) stimulation, and naive C57BL/6 and Balb/c re-matched MPs generally leads to destruction of the whole recipient fiber by the host immune system. Thus, we sponder groups were included to confirm that the assay was working properly (Fig. 4) . From each of the three tested the ability of therapeutic C57BL/6 muscle cells to integrate and survive in NUPA10hd-LSK tolerized mice. groups exhibiting both chimeric and nonchimeric mice (transplanted with 300, 3,000, and 30,000 NUPA10hd-The scheme used in these experiments is represented in Figure 3A .
transduced LSK cells, respectively), one chimeric and one nonchimeric mouse were selected to be tested by Skeletal muscle harvested from C57BL/6 mice ubiquitously expressing GFP was enzymatically dissociated, MLR. Proliferation of reconstituted Balb/c host T cells in response to C57BL/6 APC was found in all three cul-CD45 − , CD31 − , α7 integrin + Sca-1 − MPs were purified as previously described (9) (Fig. 3B) , and 3 × 10 4 sorted tures derived from the nonchimeric animals ( Fig. 4) , whereas cultures initiated from the spleen of mice dem-cells were injected into the TA muscle of transplanted Balb/c mice as well as C57BL/6 control mice that had onstrating chimerism in circulating hematopoietic cells by FACS and tolerant to a muscle transplant did not received syngenic BM. Four weeks after MP injection, limb muscles of recipients were analyzed for the pres-produce T-cell proliferation in the MLR. These results suggest that clonal deletion occurred in the mice tolerant ence of integrated GFP + myofibers (Fig. 3C ). All mice with a high level of chimerism accepted the muscle cell for satellite cell allograft. graft with no evidence of inflammatory cell infiltration DISCUSSION (Table 1, Fig. 3C ). In contrast, no GFP − myofibers were found in nonchimeric mice or those with milder level of Successful myoblast transplantations have been obtained in mice, monkeys, and even in DMD patients un-chimerism (Table 1) . As a syngenic control group, Ly 5.1 C57BL/6 mice transplanted with 3,000 Ly 5.2 der tacrolimus immunosuppression (10,20,21). However, current long-term pharmacological immunosuppressive NUPA10hd-expressing LSK cells and displaying high levels of chimerism also received MPs by intramuscular treatments required by these techniques result in numerous undesirable side effects. One promising alternative injection. As expected, all mice within this group retained GFP myofibers (Table 1) . As a control for myo-strategy to reduce graft rejection without the use of lifelong immunosuppression is the induction of lasting im-fiber rejection, C57BL/6 GFP + MPs were injected in a group of Balb/c mice transplanted with 10 6 Balb/c BM mune tolerance by establishment of mixed hematopoietic chimerism. One way to obtain sufficient chimerism cells. Surprisingly in two independent experiments, one of four mice in this group was found to contain abundant to reliably induce tolerance is to apply significant myeloablation (25) . However, this regime routinely used to positive GFP myofibers at the injection site (Table 1; data not shown). This might be due to immunosuppres-allow allogenic marrow engraftment is so toxic that it is almost exclusively used to cure lymphomas and leuke-sion caused by irradiation. Importantly, in order to ensure that detected GFP + myofibers arose from fusion of mias. Alternatively, large numbers of donor cells, usually higher than are clinically available, can be com-injected GFP + myoblasts and not of NUPA10hd-GFPexpressing HSCs, a group of Balb/c recipients was in-bined with milder myeloablative treatments to obtain sufficient chimerism (25) . Different strategies have been jected with 30,000 NUPA10hd-transduced LSK cells without receiving a following GFP + myoblast injection.
attempted to increase HSC availability, including ex vivo expansion of BM or blood-mobilized HSCs. Unfor-We did not observe any GFP + myofiber in the chimeric mice from this group (data not shown).
tunately, expanded HSC seem to have a reduced ability to maintain long-term engraftment (27) . Another attrac-
Chimeric Mice Exhibit Functional T-Cell Tolerance
tive approach is to use the highly expandable ES cells as a source of donor cells for both HSCs and tissue-As a secondary assessment of immune tolerance induction, we performed a mixed lymphocyte reaction regenerating cells (e.g., muscle progenitors). However, ES cell-derived HSCs are extremely poor at engrafting (MLR) assay, which involves a short-term coculture of bulk splenocytes recovered from transplanted animals adults. Although they have been able to efficiently repopulate the BM of irradiated recipients when trans-and irradiated allogenic APCs. This simple assay reflects tolerance induction by asking whether BM recipi-duced with HOXB4, their reconstitution of the lymphoid compartment is limited, possibly due to a direct effect ent splenocytes are induced to proliferate in response to MHC-antigen determinants on allogenic APCs. Spleen of this transcription factor on hematopoietic cell differ- entiation (18) . On the contrary, the homeodomain of an-lating the BM of immunologically mismatched recipients, allowing the induction of immunological tolerance other related HOX gene, HOXA10, when fused to NUP98 (NUPA10hd), has been shown to induce HSC expansion to myoblast transplantation. Future testing of NUPA10hdinfected ES cell-derived HSCs will be required in order in vitro and in vivo (15, 19) . We demonstrate here that NUPA10hd transduced cells are fully capable of repopu-to ascertain whether this transcription factor, similarly to extremely high (and thus clinically prohibitive) numbers 6. Gluckman, E. History of cord blood transplantation. Bone of nonmanipulated HSCs. This strategy is of particular
